These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10160489)

  • 1. French economic evaluations of influenza and influenza vaccination.
    Levy E
    Pharmacoeconomics; 1996; 9 Suppl 3():62-6. PubMed ID: 10160489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.
    Nichol KL
    Arch Intern Med; 2001 Mar; 161(5):749-59. PubMed ID: 11231710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.
    Postma MJ; Jansema P; van Genugten ML; Heijnen ML; Jager JC; de Jong-van den Berg LT
    Drugs; 2002; 62(7):1013-24. PubMed ID: 11985488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness of prophylaxis and treatment of influenza].
    Rychlik R; Heinen-Kammerer T; Rusche H; Piercy J; Scuffham P; Zöllner Y
    Dtsch Med Wochenschr; 2003 Oct; 128(43):2267-70. PubMed ID: 14574642
    [No Abstract]   [Full Text] [Related]  

  • 5. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model.
    Gerlier L; Lamotte M; Grenèche S; Lenne X; Carrat F; Weil-Olivier C; Damm O; Schwehm M; Eichner M
    Appl Health Econ Health Policy; 2017 Apr; 15(2):261-276. PubMed ID: 27943165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.
    Bridges CB; Thompson WW; Meltzer MI; Reeve GR; Talamonti WJ; Cox NJ; Lilac HA; Hall H; Klimov A; Fukuda K
    JAMA; 2000 Oct; 284(13):1655-63. PubMed ID: 11015795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations.
    Gatwood J; Meltzer MI; Messonnier M; Ortega-Sanchez IR; Balkrishnan R; Prosser LA
    Drugs; 2012 Jan; 72(1):35-48. PubMed ID: 22191794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus: results from a pilot study.
    Pisu M; Meltzer MI; Hurwitz ES; Haber M
    Pharmacoeconomics; 2005; 23(1):55-67. PubMed ID: 15693728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of influenza vaccination. Assessment for The Netherlands.
    Postma MJ; Bos JM; van Gennep M; Jager JC; Baltussen R; Sprenger MJ
    Pharmacoeconomics; 1999; 16 Suppl 1():33-40. PubMed ID: 10623374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
    Uhart M; Bricout H; Clay E; Largeron N
    Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitigation of pandemic influenza: review of cost-effectiveness studies.
    Lugnér AK; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):547-58. PubMed ID: 19941432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic value of influenza vaccination.
    de Waure C; Veneziano MA; Cadeddu C; Capizzi S; Specchia ML; Capri S; Ricciardi W
    Hum Vaccin Immunother; 2012 Jan; 8(1):119-29. PubMed ID: 22251999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness study on influenza prevention in Hong Kong.
    Fitzner KA; Shortridge KF; McGhee SM; Hedley AJ
    Health Policy; 2001 Jun; 56(3):215-34. PubMed ID: 11399347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness and socio-economic aspects of childhood influenza vaccination.
    Nichol KL
    Vaccine; 2011 Oct; 29(43):7554-8. PubMed ID: 21820477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential economic value of influenza vaccination for healthcare workers in The Netherlands.
    Meijboom MJ; Riphagen-Dalhuisen J; Hak E
    Influenza Other Respir Viruses; 2018 Jul; 12(4):457-464. PubMed ID: 29624882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US.
    Peasah SK; Meltzer MI; Vu M; Moulia DL; Bridges CB
    PLoS One; 2019; 14(4):e0213499. PubMed ID: 31034485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluations of childhood influenza vaccination: a critical review.
    Newall AT; Jit M; Beutels P
    Pharmacoeconomics; 2012 Aug; 30(8):647-60. PubMed ID: 22788257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
    Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
    Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.